gamma-aminobutyric acid has been researched along with Epilepsy, Complex Partial in 62 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Epilepsy, Complex Partial: A disorder characterized by recurrent partial seizures marked by impairment of cognition. During the seizure the individual may experience a wide variety of psychic phenomenon including formed hallucinations, illusions, deja vu, intense emotional feelings, confusion, and spatial disorientation. Focal motor activity, sensory alterations and AUTOMATISM may also occur. Complex partial seizures often originate from foci in one or both temporal lobes. The etiology may be idiopathic (cryptogenic partial complex epilepsy) or occur as a secondary manifestation of a focal cortical lesion (symptomatic partial complex epilepsy). (From Adams et al., Principles of Neurology, 6th ed, pp317-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of a new anti-epileptic medication vigabatrin in adults and children with drug-resistant epilepsy." | 7.69 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| " The patient manifested marked gingival overgrowth compatible clinically and histologically with the overgrowth induced by phenytoin, cyclosporine and calcium channel blockers." | 7.69 | Vigabatrin-induced gingival overgrowth. ( Chaushu, G; Givol, N; Katz, J; Shemer, J; Taicher, S, 1997) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 7.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 6.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 6.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "Vigabatrin is a relatively new medication used in the treatment of epilepsia." | 5.30 | Vigabatrin-induced gingival overgrowth. ( Chaushu, G; Givol, N; Katz, J; Shemer, J; Taicher, S, 1997) |
| "Vigabatrin has a definite role to play in the management of persons with intractable complex partial seizures where standard anti-epileptic therapy has failed to achieve control." | 5.29 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 5.29 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Vigabatrin is a novel antiepileptic drug designed to control seizures by raising brain gamma-aminobutyric acid (GABA) concentrations." | 5.08 | Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. ( Behar, KL; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| " The second patient complained of impotence after a rash while taking phenytoin and carbamazepine." | 3.70 | Improved sexual function in three men taking lamotrigine for epilepsy. ( Carwile, ST; Husain, AM; Miller, PP; Radtke, RA, 2000) |
| "To determine the efficacy of a new anti-epileptic medication vigabatrin in adults and children with drug-resistant epilepsy." | 3.69 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 3.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| " The patient manifested marked gingival overgrowth compatible clinically and histologically with the overgrowth induced by phenytoin, cyclosporine and calcium channel blockers." | 3.69 | Vigabatrin-induced gingival overgrowth. ( Chaushu, G; Givol, N; Katz, J; Shemer, J; Taicher, S, 1997) |
| " The concentrations of glutamate and gamma-aminobutyric acid (GABA), the brain's major inhibitory neutrotransmitter, were measured in microdialysates before and during seizures in 6 patients with complex partial epilepsy investigated before surgery." | 3.68 | Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. ( During, MJ; Spencer, DD, 1993) |
| "Vigabatrin was well tolerated, causing no clinically significant changes in laboratory parameters, brain magnetic resonance imaging, evoked potentials, cognitive function, or psychosocial tests." | 2.69 | Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. ( Dean, C; Mosier, M; Penry, K, 1999) |
| "Vigabatrin was well tolerated, compliance was high with twice-daily administration, and therapy did not result in clinically relevant drug interactions." | 2.68 | A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. ( French, JA; Mosier, M; Sommerville, K; Sussman, N; Walker, S, 1996) |
| "Gabapentin appears to increase human brain GABA levels." | 2.68 | The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. ( Behar, KL; Lamoureux, D; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| "Gabapentin has come into clinical use as adjunctive therapy in the treatment of epilepsy." | 2.68 | The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. ( Behar, KL; Lamoureux, D; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| "Vigabatrin appears to be a reasonable choice for single-drug therapy in the treatment of certain types of seizures." | 2.68 | Newer antiepileptic drugs as monotherapy: data on vigabatrin. ( Fisher, R; Kälviäinen, R; Regesta, G; Tanganelli, P, 1996) |
| "Vigabatrin is a novel antiepileptic drug designed to control seizures by raising brain gamma-aminobutyric acid (GABA) concentrations." | 2.68 | Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. ( Behar, KL; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| "Starting vigabatrin treatment reduced seizure frequency by > 50%, from six to seven per month to three." | 2.68 | Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. ( Behar, KL; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| " We increased the daily dosage to 2." | 2.68 | A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. ( French, JA; Mosier, M; Sommerville, K; Sussman, N; Walker, S, 1996) |
| "Vigabatrin was well-tolerated and did not cause clinically significant adverse drug effects when added to established anticonvulsant therapy." | 2.68 | A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. ( Beran, RG; Berkovic, SF; Buchanan, N; Danta, G; Mackenzie, R; Schapel, G; Sheean, G; Vajda, F, 1996) |
| "Gabapentin was well tolerated by patients in both dosage groups, and no patients exited the study due to adverse events, despite rapid initiation of full dose within 24 hours." | 2.68 | Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. ( Bergey, GK; Blume, WT; Crockatt, JG; Garofalo, E; LaMoreaux, L; Leiderman, DB; Morrell, MJ; Morris, HH; Penovich, PE; Pierce, M; Rosenfeld, W, 1997) |
| " Gabapentin was well tolerated by patients in both dosage groups, and no patients exited the study due to adverse events, despite rapid initiation of full dose within 24 hours." | 2.68 | Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. ( Bergey, GK; Blume, WT; Crockatt, JG; Garofalo, E; LaMoreaux, L; Leiderman, DB; Morrell, MJ; Morris, HH; Penovich, PE; Pierce, M; Rosenfeld, W, 1997) |
| " Results of outcome measures, including time to exit, completion rate, and mean time on monotherapy, showed no significant differences among dosage groups." | 2.68 | Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. ( Abou-Khalil, B; Beydoun, A; Cantrell, D; Fischer, J; Garofalo, E; Greiner, M; Harden, C; Hayes, A; Labar, DR; Pierce, M; Ramsay, RE; Sackellares, JC; Uthman, BM, 1997) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 2.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| "Gabapentin is an anti-epileptic drug (AED) that was approved in 1993 for the adjunct treatment of complex partial seizures (CPS) with and without generalization." | 2.41 | Gabapentin: a unique anti-epileptic agent. ( Dougherty, JA; Rhoney, DH, 2001) |
| " Also, the dosing of the drug in children has been complicated by negative behavioral adverse effects." | 2.41 | Gabapentin: a unique anti-epileptic agent. ( Dougherty, JA; Rhoney, DH, 2001) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 2.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| " After lamotrigine was added for better seizure control and the dosage of gabapentin was tapered, anorgasmia improved." | 1.31 | Improved sexual function in three men taking lamotrigine for epilepsy. ( Carwile, ST; Husain, AM; Miller, PP; Radtke, RA, 2000) |
| "Lamotrigine was added to the carbamazepine regimen; impotence improved with decrease in carbamazepine and increase in lamotrigine." | 1.31 | Improved sexual function in three men taking lamotrigine for epilepsy. ( Carwile, ST; Husain, AM; Miller, PP; Radtke, RA, 2000) |
| "The second patient complained of impotence after a rash while taking phenytoin and carbamazepine." | 1.31 | Improved sexual function in three men taking lamotrigine for epilepsy. ( Carwile, ST; Husain, AM; Miller, PP; Radtke, RA, 2000) |
| "Vigabatrin is a relatively new medication used in the treatment of epilepsia." | 1.30 | Vigabatrin-induced gingival overgrowth. ( Chaushu, G; Givol, N; Katz, J; Shemer, J; Taicher, S, 1997) |
| "Vigabatrin was administered in three patients, one of whom took dilantin together with vigabatrin." | 1.30 | Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? ( Chang, KH; Cheon, JE; Han, MH; Jeong, SW; Kim, SS; Kim, ST; Lee, SK; Suh, DC, 1999) |
| " Once-a-day dosing is sufficient to increase GABA." | 1.30 | Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. ( Collins, T; Hyder, F; Mattson, RH; Petroff, OA; Rothman, DL, 1999) |
| "Gabapentin has been accepted worldwide as a novel antiepileptic drug with a favourable tolerability profile." | 1.30 | Isolated ataxia as an idiosyncratic side-effect under gabapentin. ( Bittermann, HJ; Herrendorf, G; Kurth, C; Steinhoff, BJ, 1997) |
| " With a view to better defining the drug's dose-response relationships in the presence of concomitant alternative antiepileptic drugs." | 1.29 | Plasma concentrations of vigabatrin in epileptic patients. ( López, E; Quintana, B; Rodriguez, I; Sánchez-Alcaraz, A, 1996) |
| "We report the appearance of multifocal myoclonus in two adult patients treated with vigabatrin as an add-on drug for complex partial seizures." | 1.29 | Vigabatrin and multifocal myoclonus in adults with partial seizures. ( Neufeld, MY; Vishnevska, S, 1995) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 1.29 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Vigabatrin has a definite role to play in the management of persons with intractable complex partial seizures where standard anti-epileptic therapy has failed to achieve control." | 1.29 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| "Vigabatrin is a novel antiepileptic agent, whose action is based on the inhibition of gamma-aminobutyric acid (GABA) aminotransferase, the enzyme responsible for the catabolism of the neurotransmitter GABA." | 1.28 | Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. ( Ben-Menachem, E; Haegele, KD; Huebert, N; Mumford, J; Persson, LI, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 53 (85.48) | 18.2507 |
| 2000's | 9 (14.52) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crespo Pérez, L | 1 |
| Moreira Vicente, V | 1 |
| Cano Ruiz, A | 1 |
| Gobernado Serrano, JM | 1 |
| Cobo Ibañez, N | 1 |
| Milicua Salamero, JM | 1 |
| Mueller, SG | 1 |
| Weber, OM | 1 |
| Duc, CO | 1 |
| Meier, D | 1 |
| Russ, W | 1 |
| Boesiger, P | 1 |
| Wieser, HG | 1 |
| Petroff, OA | 13 |
| Hyder, F | 7 |
| Rothman, DL | 12 |
| Mattson, RH | 12 |
| Wolf, SM | 1 |
| Shinnar, S | 1 |
| Kang, H | 1 |
| Gil, KB | 1 |
| Moshé, SL | 1 |
| Jadresic, D | 1 |
| Cramer, J | 1 |
| Vachon, L | 1 |
| Desforges, C | 1 |
| Sussman, NM | 1 |
| Short, C | 1 |
| Cooke, L | 1 |
| Vogt, H | 1 |
| Krämer, G | 1 |
| Lleu, PL | 1 |
| Labiner, D | 1 |
| Weinand, M | 1 |
| Huxtable, RJ | 1 |
| Buchanan, N | 2 |
| Fromm, GH | 1 |
| Arzimanoglou, A | 1 |
| Stolarek, I | 1 |
| Blacklaw, J | 1 |
| Forrest, G | 1 |
| Brodie, MJ | 1 |
| Löscher, W | 2 |
| Gram, L | 1 |
| Stefan, H | 1 |
| During, MJ | 1 |
| Spencer, DD | 1 |
| Meldrum, BS | 1 |
| Pierce, MW | 3 |
| Shu, VS | 1 |
| Ben-Menachem, E | 3 |
| Söderfelt, B | 1 |
| Hamberger, A | 1 |
| Hedner, T | 1 |
| Persson, LI | 2 |
| French, JA | 1 |
| Mosier, M | 2 |
| Walker, S | 1 |
| Sommerville, K | 1 |
| Sussman, N | 1 |
| Behar, KL | 6 |
| Lamoureux, D | 1 |
| Tallian, KB | 1 |
| Nahata, MC | 1 |
| Lo, W | 1 |
| Tsao, CY | 1 |
| Neufeld, MY | 1 |
| Vishnevska, S | 1 |
| Mackenzie, RA | 1 |
| Fisher, R | 1 |
| Kälviäinen, R | 1 |
| Tanganelli, P | 2 |
| Regesta, G | 2 |
| Duncan, JS | 1 |
| Schapel, GJ | 1 |
| Black, AB | 1 |
| Lam, EL | 1 |
| Robinson, M | 1 |
| Dollman, WB | 1 |
| Bachmann, D | 1 |
| Ritz, R | 1 |
| Wad, N | 1 |
| Haefeli, WE | 1 |
| Beran, RG | 1 |
| Berkovic, SF | 1 |
| Danta, G | 1 |
| Mackenzie, R | 1 |
| Schapel, G | 1 |
| Sheean, G | 1 |
| Vajda, F | 1 |
| Katz, J | 1 |
| Givol, N | 1 |
| Chaushu, G | 1 |
| Taicher, S | 1 |
| Shemer, J | 1 |
| Rodríguez Moreno, E | 1 |
| Acilona, V | 1 |
| Boza, F | 1 |
| Ortega, JE | 1 |
| Carballo, M | 1 |
| Palomino, A | 1 |
| Arenas, C | 1 |
| Sánchez-Alcaraz, A | 1 |
| Quintana, B | 1 |
| Rodriguez, I | 1 |
| López, E | 1 |
| Bergey, GK | 1 |
| Morris, HH | 2 |
| Rosenfeld, W | 1 |
| Blume, WT | 1 |
| Penovich, PE | 1 |
| Morrell, MJ | 1 |
| Leiderman, DB | 1 |
| Crockatt, JG | 1 |
| LaMoreaux, L | 1 |
| Garofalo, E | 2 |
| Pierce, M | 2 |
| Beydoun, A | 1 |
| Fischer, J | 1 |
| Labar, DR | 1 |
| Harden, C | 1 |
| Cantrell, D | 1 |
| Uthman, BM | 1 |
| Sackellares, JC | 1 |
| Abou-Khalil, B | 1 |
| Ramsay, RE | 1 |
| Hayes, A | 1 |
| Greiner, M | 1 |
| Shokry, A | 1 |
| Steinhoff, BJ | 1 |
| Herrendorf, G | 1 |
| Bittermann, HJ | 1 |
| Kurth, C | 1 |
| Vaquerizo, J | 1 |
| Romero-Rodríguez, JC | 1 |
| González-Roncero, A | 1 |
| Gómez-Marcos, A | 1 |
| Herranz, JL | 1 |
| Dean, C | 1 |
| Penry, K | 1 |
| Kim, SS | 1 |
| Chang, KH | 1 |
| Kim, ST | 1 |
| Suh, DC | 1 |
| Cheon, JE | 1 |
| Jeong, SW | 1 |
| Han, MH | 1 |
| Lee, SK | 1 |
| Trinka, E | 1 |
| Moroder, T | 1 |
| Nagler, M | 1 |
| Staffen, W | 1 |
| Ladurner, G | 1 |
| Tennison, M | 1 |
| Gatzonis, S | 1 |
| Laiaki, A | 1 |
| Chioni, A | 1 |
| Siafakas, A | 1 |
| Zournas, C | 1 |
| Mantouvalos, V | 1 |
| Hamer, HM | 1 |
| Dodrill, CB | 1 |
| Arnett, JL | 1 |
| Hayes, AG | 1 |
| Garofalo, EA | 1 |
| Greeley, CA | 1 |
| Greiner, MJ | 1 |
| Collins, T | 1 |
| Spanaki, MV | 1 |
| Siegel, H | 1 |
| Kopylev, L | 1 |
| Fazilat, S | 1 |
| Dean, A | 1 |
| Liow, K | 1 |
| Gaillard, WD | 1 |
| Theodore, WH | 1 |
| Maj, R | 1 |
| Fariello, RG | 1 |
| Pevarello, P | 1 |
| Varasi, M | 1 |
| McArthur, RA | 1 |
| Salvati, P | 1 |
| Husain, AM | 1 |
| Carwile, ST | 1 |
| Miller, PP | 1 |
| Radtke, RA | 1 |
| Collins, TL | 1 |
| Dougherty, JA | 1 |
| Rhoney, DH | 1 |
| Olsen, RW | 1 |
| Bureau, M | 1 |
| Houser, CR | 1 |
| Delgado-Escueta, AV | 1 |
| Richards, JG | 1 |
| Möhler, H | 1 |
| Mumford, J | 1 |
| Haegele, KD | 1 |
| Huebert, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
10 reviews available for gamma-aminobutyric acid and Epilepsy, Complex Partial
| Article | Year |
|---|---|
[Anticonvulsant hypersensitivity syndrome: an entity to be remembered].
Topics: Adolescent; Amines; Anemia, Hemolytic; Anticonvulsants; Astrocytoma; Brain Neoplasms; Carbamazepine; | 2009 |
[Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic].
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, | 1995 |
Gabapentin: discussion.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drugs, Inv | 1994 |
Handling seizure data: special problems.
Topics: Anticonvulsants; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Therapy, Combinati | 1993 |
Magnetic resonance spectroscopy.
Topics: Aspartic Acid; Brain; Creatinine; Epilepsy; Epilepsy, Complex Partial; Epilepsy, Temporal Lobe; gamm | 1996 |
[Tiagabine: recent findings and recommendations for dosage].
Topics: Dose-Response Relationship, Drug; Epilepsy, Complex Partial; gamma-Aminobutyric Acid; Humans; Neurot | 1998 |
Clinical and EEG findings in complex partial status epilepticus with tiagabine.
Topics: Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1999 |
New NMR measurements in epilepsy. Measuring brain GABA in patients with complex partial seizures.
Topics: Brain; Epilepsy; Epilepsy, Complex Partial; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spec | 1999 |
Proton MRS: GABA and glutamate.
Topics: Adult; Animals; Astrocytes; Brain; Epilepsy, Complex Partial; Female; gamma-Aminobutyric Acid; Gluta | 2000 |
Gabapentin: a unique anti-epileptic agent.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Complex Part | 2001 |
19 trials available for gamma-aminobutyric acid and Epilepsy, Complex Partial
| Article | Year |
|---|---|
Gabapentin toxicity in children manifesting as behavioral changes.
Topics: Acetates; Affect; Aggression; Amines; Anticonvulsants; Behavior; Child; Cyclohexanecarboxylic Acids; | 1995 |
Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial.
Topics: Adolescent; Adult; Ambulatory Care; Anticonvulsants; Clinical Protocols; Dose-Response Relationship, | 1995 |
Vigabatrin and lamotrigine in refractory epilepsy.
Topics: Anticonvulsants; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Epilepsy, Complex | 1994 |
Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1995 |
A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort.
Topics: Adolescent; Adult; Anticonvulsants; Double-Blind Method; Electroencephalography; Epilepsy, Complex P | 1996 |
The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 1996 |
Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose.
Topics: Adult; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Epilepsy, Complex Partial; Female; | 1996 |
Newer antiepileptic drugs as monotherapy: data on vigabatrin.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cross-Over Studies | 1996 |
Combination vigabatrin and lamotrigine therapy for intractable epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Drug Combinations; Epilepsy, Complex Partial; Female; gamma-Amin | 1996 |
Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy.
Topics: Adult; Anticonvulsants; Epilepsy, Complex Partial; Female; gamma-Aminobutyric Acid; Humans; Male; Mi | 1996 |
A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1996 |
Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Cross-Over Studies; Epilepsy, Complex Parti | 1996 |
Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Rel | 1997 |
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecar | 1997 |
Vigabatrin increases human brain homocarnosine and improves seizure control.
Topics: Adult; Anticonvulsants; Carnosine; Dose-Response Relationship, Drug; Epilepsy, Complex Partial; Fema | 1998 |
Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combina | 1999 |
Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures.
Topics: Adult; Ammonia; Anticonvulsants; Astrocytes; Epilepsy, Complex Partial; Female; gamma-Aminobutyric A | 1999 |
Cognitive abilities and adjustment with gabapentin: results of a multisite study.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Epilepsy | 1999 |
The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism.
Topics: Adult; Anticonvulsants; Brain; Cerebrovascular Circulation; Double-Blind Method; Epilepsy, Complex P | 1999 |
33 other studies available for gamma-aminobutyric acid and Epilepsy, Complex Partial
| Article | Year |
|---|---|
Effects of vigabatrin on brain GABA+/Cr signals in focus-distant and focus-near brain regions monitored by 1H-NMR spectroscopy.
Topics: Adolescent; Adult; Brain; Chromium Radioisotopes; Epilepsy, Complex Partial; Female; gamma-Aminobuty | 2003 |
Brain homocarnosine and seizure control of patients taking gabapentin or topiramate.
Topics: Adult; Amines; Anticonvulsants; Brain Chemistry; Carnosine; Cyclohexanecarboxylic Acids; Drug Therap | 2006 |
Acute pancreatitis associated with dual vigabatrin and lamotrigine therapy.
Topics: Acute Disease; Adult; Amylases; Anticonvulsants; Epilepsy, Complex Partial; gamma-Aminobutyric Acid; | 1994 |
Hypomania induced by gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Dose-Response Rela | 1995 |
Neuroactive amino acids in synaptosomes from focal and nonfocal temporal lobe tissue of patients with intractable complex partial seizures.
Topics: Adult; Amino Acids; Animals; Epilepsy, Complex Partial; Female; gamma-Aminobutyric Acid; Glutamic Ac | 1994 |
Vigabatrin use in 72 patients with drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilep | 1994 |
Vigabatrin and complex partial status.
Topics: Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epilepsy, Complex Partial; Evoke | 1994 |
Plasma GABA and seizure control with vigabatrin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminocaproates; Anticonvulsants; Epilepsy, Complex Parti | 1993 |
Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain.
Topics: Adolescent; Adult; Dialysis; Electrodes, Implanted; Electroencephalography; Epilepsy, Complex Partia | 1993 |
Intracerebral microdialysis and seizure initiation.
Topics: Dialysis; Electroencephalography; Epilepsy, Complex Partial; Extracellular Space; gamma-Aminobutyric | 1993 |
Gabapentin associated with aggressive behavior in pediatric patients with seizures.
Topics: Acetates; Adolescent; Age Factors; Aggression; Amines; Anticonvulsants; Child; Child Behavior Disord | 1996 |
Vigabatrin and multifocal myoclonus in adults with partial seizures.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsy, Complex Partial; Female; gamma-Aminobutyri | 1995 |
Examining the role of vigabatrin.
Topics: Adolescent; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Complex Partial; gamma-Aminobutyri | 1996 |
Vigabatrin dosing during haemodialysis.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Monitoring; Epilepsy, Complex Partial; gamma | 1996 |
Vigabatrin-induced gingival overgrowth.
Topics: Adult; Anticonvulsants; Calcium Channel Blockers; Cyclosporine; Epilepsy, Complex Partial; Female; F | 1997 |
[Concurrence of short and long lasting episodes of nocturnal paroxysmal dystonia in an epileptic patient].
Topics: Adult; Anticonvulsants; Carbamazepine; Dystonia; Electroencephalography; Epilepsy, Complex Partial; | 1997 |
Plasma concentrations of vigabatrin in epileptic patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1996 |
[Trials with gabapentin monotherapy in patients with complex partial or secondary generalized seizures].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Do | 1997 |
Isolated ataxia as an idiosyncratic side-effect under gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cerebellar Ataxia; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
[Partial complex status epilepticus: diagnostic difficulties].
Topics: Anticonvulsants; Child; Crime; Diagnosis, Differential; Drug Therapy, Combination; Electroencephalog | 1998 |
Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity?
Topics: Adult; Anticonvulsants; Corpus Callosum; Epilepsy, Complex Partial; Female; gamma-Aminobutyric Acid; | 1999 |
Localized 1H NMR measurements of 2-pyrrolidinone in human brain in vivo.
Topics: Adult; Anticonvulsants; Body Water; Creatine; Epilepsy, Complex Partial; Female; gamma-Aminobutyric | 1999 |
Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity?
Topics: Anticonvulsants; Corpus Callosum; Epilepsy, Complex Partial; gamma-Aminobutyric Acid; Humans; Magnet | 1999 |
A case of fever following antiepileptic treatment.
Topics: Adult; Anticonvulsants; Body Temperature Regulation; Carbamazepine; Drug Therapy, Combination; Epile | 1999 |
Successful treatment with gabapentin in the presence of hypersensitivity syndrome to phenytoin and carbamazepine: a report of three cases.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Hypersens | 1999 |
Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures.
Topics: Administration, Oral; Adult; Anticonvulsants; Brain; Brain Chemistry; Carnosine; Dose-Response Relat | 1999 |
Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures.
Topics: Acetates; Alanine; Amines; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Benzylamines; Carba | 1999 |
Improved sexual function in three men taking lamotrigine for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; | 2000 |
A comparison of four new antiepileptic medications.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose | 2000 |
Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures.
Topics: Adult; Aged; Carnosine; Epilepsy, Complex Partial; Female; gamma-Aminobutyric Acid; Humans; Magnetic | 2001 |
Topiramate rapidly raises brain GABA in epilepsy patients.
Topics: Administration, Oral; Anticonvulsants; Brain Chemistry; Carnosine; Dose-Response Relationship, Drug; | 2001 |
GABA/benzodiazepine receptors in human focal epilepsy.
Topics: Amygdala; Autoradiography; Brain Mapping; Dominance, Cerebral; Electroencephalography; Epilepsies, P | 1992 |
Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid.
Topics: Adult; Aminocaproates; Anticonvulsants; Carnosine; Electroencephalography; Epilepsy, Complex Partial | 1991 |